

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Honliv Healthcare Management Group Company Limited

宏力醫療管理集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9906)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO QUARTERLY UPDATE ON STATUS OF RESUMPTION

This announcement is made by Honliv Healthcare Management Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.24A of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated 19 March 2026, 25 March 2026, 21 April 2026 and 18 June 2026 (the “**Announcements**”) in relation to, among other things, (i) the resignation of PricewaterhouseCoopers (“**PwC**”) as auditor; (ii) the appointment of HLB Hodgson Impey Cheng Limited (“**HLB**”) as the new auditor; (iii) the delay in publication of 2025 annual results; and (iv) the quarterly update on status of resumption. Unless the context requires otherwise, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

QUARTERLY UPDATE ON RESUMPTION PROGRESS

The board of directors (the “**Board**”) would like to further update shareholders and potential investors of the Company on the latest developments with the Company’s business and progress with fulfilling the Resumption Guidance.

Resumption Plan and Timetable

the Board sets out below a summary of the specific steps being taken to fulfil each of the Resumption Guidance, together with the anticipated timetable for their completion:

Resumption Condition	Actions Being Taken	Indicative Timeline
Independent forensic investigation into the Loan and related fund transfers	Zhonghui CPA (the “ Independent Forensic Investigator ”) conducting fieldwork; investigation scope expanded to forensic work following Resumption Guidance	On or around 19 July 2026
Independent internal control review	Zhonghui Management Consultation Co., Ltd. (the “ IC Consultant ”) conducting review	On or around 22 July 2026
Publication of outstanding financial information (2025 Annual Results)	HLB is conducting outstanding audit procedures	End of July 2026, subject to completion of the Independent Investigation and the independent internal control review
Assessment of regulatory concerns regarding management integrity, competence and/or character	To be assessed upon receipt of the Independent Investigation findings	Following completion of Independent Investigation

The Board will promptly assess the impact of any further delays and make appropriate adjustments to the above timetable, and will announce any material changes as and when appropriate.

Update on the Independent Investigation

As disclosed in the announcement dated 18 June 2026, the Independent Committee established by the Audit Committee has appointed Zhonghui Certified Public Accountants LLP (中匯會計師事務所(特殊普通合夥)) (the “**Independent Forensic Investigator**”) to assist them in conducting the Independent Investigation.

The scope of the Independent Investigation principally covers the bank loan of RMB63 million obtained from a local PRC branch of Bank of China. The Independent Forensic Investigator has been engaged to conduct a comprehensive investigation into, among other things, the authenticity and compliance of the bank loan and the related procurement transaction, the fund flow and use of the loan proceeds, and whether there exist any irregular use or misappropriation of funds, undisclosed connected transactions, financial fraud or other irregularities. The RMB63 million bank loan has been fully repaid as of the date of this announcement.

As of the date of this announcement, the Independent Forensic Investigator is still conducting fieldwork. Following the Company’s receipt of the Stock Exchange’s Resumption Guidance on 13 May 2026, the scope of the Independent Investigation was expanded to include forensic work in relation to the bank loan and the transfer of the loan proceeds. As a result, additional time has been required for the fieldwork to be completed.

Based on the Independent Forensic Investigator’s current indication to the Company (which has not been independently verified by the Company), the Independent Investigation is expected to be completed on or around 19 July 2026. The Company will publish further announcement(s) to inform Shareholders of the key findings of the Independent Investigation as and when appropriate.

Update on the Internal Control Review

As disclosed in the announcement dated 18 June 2026, the Company has appointed Zhonghui Management Consultation Co., Ltd. (中匯管理諮詢有限公司) (the “**Independent Internal Control Consultant**”) to conduct the Internal Control Review. The Internal Control Review will examine, among other areas, the Company’s policies and procedures in relation to: (i) corporate governance; (ii) monetary funds and payment; (iii) procurement and supplier management; (iv) financial accounting and reporting; and (v) related party transaction management.

The Independent Internal Control Consultant has commenced the Internal Control Review. As of the date of this announcement, the Internal Control Review is expected to be completed on or around 22 July 2026. Upon completion of the Internal Control Review, the Company will implement the recommended remedial actions and reinforcement measures, and will make further announcement(s) in respect thereof.

Update on publishing outstanding financial information

As of the date of this announcement, HLB is still in the process of performing subsequent audit procedures as well as preparing and finalizing the 2025 Annual Results based on the observations and findings of the Independent Investigation. The Company is actively cooperating with HLB to compile and provide the necessary information and documents as required by the auditor to complete the 2025 Annual Results. The Company will take all necessary steps to publish the 2025 Annual Results and despatch the 2025 Annual Report as soon as possible.

Based on the current progress, it is expected that the 2025 Annual Results will be published by the end of July, subject to completion of the Independent Investigation and the independent internal control review. The Board further announces that, in light of the delay in the publication of the 2025 Annual Results, the Company will publish a further announcement to inform Shareholders of the date of the meeting of the Board to consider and approve the 2025 Annual Results as and when appropriate.

Updates on other resumption conditions

The Company will assess whether there is any regulatory concern about the integrity, competence and/or character of the Group's management and/or any persons with substantial influence over the Company's management and operations based on the findings of the Independent Investigation. Upon the completion of the Independent Investigation, the Company will make further assessment on this issue as and when appropriate.

The Company will continue to keep its Shareholders and potential investors abreast of any relevant material development by making further announcement(s) as and when appropriate in accordance with the requirements under the Listing Rules. The Company will continue to work closely with its professional advisers and proactively take all necessary and appropriate steps to comply with the Resumption Guidance, with the aim to resume trading in its shares on the Stock Exchange as soon as practicable.

Business Operation

The Company is a healthcare services provider in the PRC. The Board confirms that the business operations and development of the Group remain as usual in all material aspects and in the same manner as it has operated prior to the trading suspension.

The Group's principal operating subsidiary, Honliv Hospital, continues to operate and provide medical services to patients. As of the date of this announcement, the loan of RMB63 million has been repaid, and thus the Board does not consider the matter to have any material adverse impact on the Group's daily business operations or financial position.

The Board has continued to assess and monitor the impact (if any) of the suspension of trading in the Shares on the operations and financial performance of the Group. As at the date of this announcement, the Board is not aware of any material adverse impact of the trading suspension on the Group's business operations.

CONTINUED SUSPENSION OF TRADING

Trading in the Shares on the Stock Exchange was suspended with effect from 9:00 a.m. on 20 March 2026 and will continue to be suspended, pending the fulfilment of the Resumption Guidance and the grant of approval by the Stock Exchange for the resumption of trading of the Shares. For further details in relation to the Resumption Guidance, please refer to the announcement of the Company dated 18 May 2026.

Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By order of the Board
Honliv Healthcare Management Group Company Limited
Mr. Qin Yan
Chairman

Hong Kong, 6 July 2026

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Qin Yan, Mr. Wang Zhongtao and Ms. Li Yanhong as the executive Directors, Mr. Qin Hongchao as the non-executive Director and Mr. Zhao Chun, Mr. Sun Jigang and Mr. Jiang Tianfan as the independent non-executive Directors.